AstraZeneca: Imfinzi approved by the EU in lung cancer

(CercleFinance.com) - AstraZeneca announces that Imfinzi (durvalumab) has been approved by the European Union as monotherapy for adult patients with limited-stage small-cell lung cancer (LS-SCLC) who have not progressed after platinum-based chemoradiotherapy.


This approval is based on a Phase III study showing a 27% reduction in the risk of death and a three-year survival rate of 57% with Imfinzi versus 48% with placebo.

This is the first immunotherapy approved in Europe for this indication, the laboratory says.


Copyright (c) 2025 CercleFinance.com. All rights reserved.